Brind.

Analyst Report Compares Perrigo and Eton Pharmaceuticals Stock Profiles

1 report, 1 independent Updated Sep 22
AI-generated briefing. Brind wrote this from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.

What happened

Some supportReported by 1 outlet

A report compared Perrigo Company Plc and Eton Pharmaceuticals, noting that both are small-cap healthcare firms. The analysis detailed that Perrigo has a beta of 0.59, indicating its share price is 41% less volatile than the S&P 500, while Eton Pharmaceuticals has a beta of 0.9. Perrigo also reported 95.9% institutional ownership compared to 27.9% for Eton Pharmaceuticals.

From tickerreport.com

Why it matters

Some supportBrind's analysis of the reports

The report found that analysts view Perrigo Company Plc as more favorable than Eton Pharmaceuticals, citing Perrigo's higher probable upside potential of 35.29% versus Eton Pharmaceuticals' 19.53%. This comparison provides insight into the differing risk profiles and institutional backing of the two companies.

From tickerreport.com

Who's involved

  • Perrigo Company PlcPharmaceutical company whose stock is analyzed for volatility and institutional ownership.

Who could feel it

Possible knock-on effects

These are possibilities Brind reasoned out, not predictions, and not advice. Most are not stated in any report.

  • Perrigo Company PlcSpeculative

    Perrigo Company Plc might see changes in investment demand based on the favorable upside potential and lower P/E ratio assessment mentioned in the report.

Keep exploring

The entities involved

Coverage

Newest first; wire copies grouped